Loading clinical trials...
Loading clinical trials...
The Analgesic Efficacy and Safety of Topical Patches (Loxoprofen Sodium Patch) in Patients With Herpes Zoster
Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia. Although early antiviral therapy limits viral replication, its analgesic effect is insufficient, and many patients experience inadequate relief despite stepwise use of non-opioids and opioids. Topical NSAIDs offer a promising alternative by delivering localized analgesia with reduced systemic exposure. Therefore, investigators hypothesize that loxoprofen sodium patch may effectively reduce the severity of HZ pain without significantly increasing adverse events.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Beijing Tiantan Hospital, Beijing, Beijing 100070
Beijing, China
Start Date
December 15, 2025
Primary Completion Date
September 30, 2027
Completion Date
December 31, 2027
Last Updated
January 30, 2026
750
ESTIMATED participants
Conventional therapy group
DRUG
Loxoprofen sodium patch combined with conventional therapy group
DRUG
Lead Sponsor
Beijing Tiantan Hospital
NCT06346132
NCT07351968
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions